WASHINGTON -Government advisers will consider Wednesday whether a GlaxoSmithKline vaccine should be approved even though the company’s study of the anti-diarrhea drug did not follow U.S. regulations.
WASHINGTON -Government advisers will consider Wednesday whether a GlaxoSmithKline vaccine should be approved even though the company’s study of the anti-diarrhea drug did not follow U.S. regulations.
